Medication info
Telmitriwonjeong 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Telmitriwonjeong 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›Strength being verifiedAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Ilseong IS Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500494 · Approved 2025.03.05 · Insurance code 655404790

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet of this medication once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan); however, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medication 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medication 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment, but treatment should be initiated at a low dose in patients with severe renal impairment, with gradual dose increases. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during rosuvastatin treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; it may be adjusted to a maintenance dose if greater LDL cholesterol reduction is required. A maintenance dose of 10 milligrams once daily controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Ilseong IS Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease.
View approved original text

This medication is used in patients with primary hypertension where blood pressure control is inadequate with telmisartan and amlodipine combination therapy. Additionally, rosuvastatin calcium is used as an adjunct therapy when dietary management and exercise are insufficient for controlling hypercholesterolemia and hyperlipidemia. This drug is indicated for primary hypercholesterolemia, heterozygous familial hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. Rosuvastatin lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and assisting in dietary management for patients with type III dysbetalipoproteinemia. Furthermore, in patients at high risk for cardiovascular disease, it helps reduce the risk of stroke, myocardial infarction, and vascular reconstructive surgery. Thus, this medication improves cardiovascular health by adequately managing blood pressure and cholesterol levels.

How to take

Adult dose

Take 1 tablet of this medication once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan); however, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medication 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medication 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment, but treatment should be initiated at a low dose in patients with severe renal impairment, with gradual dose increases. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during rosuvastatin treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; it may be adjusted to a maintenance dose if greater LDL cholesterol reduction is required. A maintenance dose of 10 milligrams once daily controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication should not be used during pregnancy. Extra caution is needed during early pregnancy, and treatment should be discontinued immediately if pregnancy is confirmed. Patients allergic to any component of this drug or those with certain conditions should not take it. For example, those with hereditary angioedema or severe liver or kidney dysfunction should avoid its use. Elderly patients or those with significantly low blood pressure or impaired liver function should use this medication with more caution, requiring regular blood tests and health monitoring. If symptoms like muscle pain or weakness occur, consult a doctor immediately, as this medication can cause muscle-related side effects, and regular muscle examinations are also recommended. This medication can interact with other drugs, so it is crucial to inform healthcare providers about any other medication being taken, especially antihypertensives, diuretics, or anticoagulants. Women of childbearing potential should use appropriate contraceptives, and breastfeeding mothers should avoid taking this medication or stop breastfeeding. In cases of overdose, symptoms such as low blood pressure, dizziness, and severe muscle pain may occur, and immediate medical attention is required. This medication has not been established as safe for children and is not recommended. During treatment, caution should be exercised while driving or operating machinery as dizziness or drowsiness may occur.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified bowel disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, erectile dysfunction, increased sweating, flushing, allergy, fever, leg pain, fatigue, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory abnormalities, involuntary muscle contractions, visual disturbances, conjunctivitis, ear pain, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disease, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, epistaxis, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, cerebrovascular disease, angioedema, angioedema, erythema multiforme, vasculitis, thrombocytopenia, thrombocytopenia, headache, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, peripheral neuropathy, tremors, appetite loss, dysphagia, pancreatitis, gingival hyperplasia, allergic reaction, burning sensation, fatigue, rigidity, weight gain, weight loss, osteoarthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, abnormal dreams, depersonalization, dyspnea, angioedema, rash, erythematous rash, papular rash, diplopia, eye pain, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, heart failure, irregular pulse, ectopic beats, skin discoloration, dry skin, hair loss, dermatitis, muscle weakness, single contraction, coordination disorders, generalized muscle tension, cold, moist skin, apathy, anxiety, amnesia, gastritis, increased appetite, loose stools, rhinitis, urinary disorders, polyuria, abnormal olfaction, taste disorder, abnormal eye control, xerophthalmia, gynecomastia, jaundice, elevated liver enzymes, leukopenia, confusion, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity reaction, toxic epidermal necrolysis, headache, dizziness, constipation, nausea, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia and systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, excessive peripheral vasodilation, reflex tachycardia, systemic hypotension, shock, non-cardiogenic pulmonary edema, headache, dizziness, weakness, cough, nausea, fatigue, weakness, edema, facial edema, lower limb edema, angioedema, pruritus, hypersensitivity reaction, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, urinary tract infection, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, elevated uric acid, impaired liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light; it should be stored in a container that does not allow light to penetrate. Furthermore, it is important to maintain a room temperature between 1°C and 30°C when storing the medication. Storing it this way will safely preserve the effectiveness of the drug.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.